Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Cirius Therapeutics logo — Pioneering the future of liver and metabolic disease treatme...

Cirius Therapeutics

Pioneering the future of liver and metabolic disease treatment with innovative insulin sensitizers.

Founded 2015 Series A Total: $49.00M Biopharma, Biotechnology +3

General Information

Company Name Cirius Therapeutics
Founded Year 2015
Founders / Decision Makers
Team member
Industries Biopharma, Biotechnology, Health and Wellness +2
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Cirius Therapeutics. To contact Cirius Therapeutics, visit ciriustx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Cirius Therapeutics compare?

A PDF of Cirius Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Cirius Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Cirius Therapeutics

Cirius Therapeutics is a clinical-stage company focused on developing treatments for non-alcoholic steatohepatitis (NASH). They are pioneering the future of liver and metabolic disease treatment with innovative insulin sensitizers. The company's flagship product, MSDC-0602K, a next-generation insulin sensitizer, is currently in a Phase 2b clinical trial. This drug aims to address the root cause of NASH through a novel insulin-sensitizing mechanism. Founded in 2015 and headquartered in Kalamazoo, Michigan, Cirius Therapeutics is dedicated to creating innovative therapies for liver and metabolic diseases. The company secured a $9.00M Series A investment on 30 August 2018 with funding from notable investors including Novo Holdings, Adams Street Partners, and Frazier Healthcare Partners. With its focus on high-impact biopharmaceuticals and a strong track record in the health and wellness industry, Cirius Therapeutics is poised for growth and potential breakthroughs in the treatment of liver and metabolic diseases.

Business keywords: Cirius Therapeutics, insulin sensitizer, MSDC-0602K, non-alcoholic steatohepatitis, NASH treatment, liver disease, metabolic disease, clinical-stage company, Phase 2b clinical trial, innovative therapies, pathophysiology, biopharmaceutical industry, clinical research, drug development

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $9.00M 3
Novo Holdings Adams Street Partners Frazier Healthcare Partners
Novo Holdings, Adams Street Partners +1
30 Aug 2018
Series A $40.00M 5
Novo Holdings Renaissance Venture Capital Adams Street Partners
Novo Holdings, Renaissance Venture Capital +3
11 Apr 2017

Cirius Therapeutics Alternatives & Competitors

View All Alternatives
Cirius Therapeutics vs
89bio
89bio United States

Developing and commercializing innovative therapies for the treatment of liver and cardio-metabolic...

Post-IPO Equity
123 employees
Biopharma, Biotechnology
Cirius Therapeutics vs
Madrigal Pharmaceuticals
Madrigal Pharmaceuticals United States

Madrigal is focused on delivering novel therapeutics for MASH, a serious liver disease.

IPO
1129 employees
Biopharma, Biotechnology
Cirius Therapeutics vs
GENFIT
GENFIT France

Dedicated to improving the lives of patients with liver diseases characterized by high unmet medical...

Post-IPO Equity
201 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Cirius Therapeutics

Pioneering the future of liver and metabolic disease treatment with innovative insulin sensitizers.
Cirius Therapeutics was founded in 2015.
Cirius Therapeutics operates in Biopharma, Biotechnology, Health and Wellness, Medical Devices and Pharmaceutical. Its work centres on Cirius Therapeutics, insulin sensitizer, MSDC-0602K and non-alcoholic steatohepatitis.
Cirius Therapeutics has completed 2 funding rounds, raising a total of $49.00M. The latest funding stage is Series A.
Top alternatives and competitors to Cirius Therapeutics include 89bio, Madrigal Pharmaceuticals, GENFIT, Inversago Pharma, Sciwind Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cirius Therapeutics and 89bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Cirius Therapeutics, https://bouncewatch.com/company/cirius-therapeutics, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout